Navigation Links
GVHD in Medical News

REGiMMUNE to present GvHD data at the 50th ASH Annual Meeting

Mountain View, CA December 5, 2008 REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company's potential therapeutic treatment for Graft versus Host Disease (GvHD) at the Am...

TNF Protein Can Predict GVHD Bone Marrow Transplant Recipients

The outcome of bone marrow transplant could be determined in just one week by measuring levels of a protein called tumor necrosis factor (TNF). // The inflammatory marker can help doctors identify which patients will develop graft vs. host disease (GVHD), the most commonly observed complication fol...

DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the seco...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

Damon Runyon Cancer Research Foundation awards $2.7M to 7 top young clinical investigators

... disease (GvHD) in cancer patients treated with bone marrow transplantation. His hypothesis is that regulatory T cells (Treg) can be used to suppress gvhd while preserving beneficial anti-tumor immunity. This work could have significant translational implications by reducing GvHD-associated mortality, t...

DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease

...dpoints such as the proportion of patients free of gvhd at Day 50 (p-value 0.05) and Day 80 (p-value 0.005...he clinically relevant determination of whether GI gvhd patients at Day 30 (the end of treatment) had a durable gvhd treatment response as measured by whether or not t...

UNC study hints at new approaches to prevent transplant rejection

...lung and skin. Not only did these findings implicate TH17 cells in the disease, but they also generated one of the first mouse models to display acute gvhd skin changes consistent with the most common manifestations of the disease in humans. Having identified the role TH17 cells play in the disease, ...

New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow, Stem Cell Transplants

...ment appears to be safe and effective in combating gvhd -- with about 40 percent of the patients showing c... Annual Scientific Meeting in Washington, D.C. gvhd is a common complication of an allogeneic bone mar...n, according to the National Institutes of Health. gvhd is the term used when a donor's immune cells attac...

New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients

...ts 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with gvhd or those with hematologic malignancies with prolonged neutropenia from chemotherapy. In October 2006, the FDA approved NOXAFIL Oral Suspension for t...

Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study

...e outcome of this study and the potential shown by Rhitol(TM). This product would fulfill a significant unmet medical need since patients with chronic gvhd resistant or intolerant to immunosuppressive drugs have no other standard treatment option available to them and this disease can subsequently develop...

ATIR Classified as "Cell Based" Medicinal Product by the EMEA

...s Pharma. About ATIR ATIR is designed to prevent life-threatening acute gvhd by eliminating the immune cells from the donor graft that otherwise attack ...wing rapid and safe donor immune reconstitution post transplantation. Acute gvhd is a major complication of allogeneic bone marrow transplantations. By prev...
GVHD in Medical Technology

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmato...

DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the seco...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations

...titution following a mismatched bone marrow transplantation. Nineteen end stage blood cancer patients were treated with no cases of grade III/IV acute gvhd occurring within the first 100 days after ATIR(TM) infusion, showing the feasibility and tolerability of the addition of ATIR(TM) in combination with ...

Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany

.... About ATIR(TM) ATIR(TM) is designed to prevent life-threatening acute gvhd by eliminating the immune cells from the donor graft that otherwise attack ...wing rapid and safe donor immune reconstitution post transplantation. Acute gvhd is a major complication of allogeneic bone marrow transplantations. By prev...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

...rding the potential use of orBec® for the treatment of gastrointestinal gvhd and the prospects for regulatory filings for orBec®. Where possible, DO... factors which may affect the future use of orBec® for gastrointestinal gvhd include the risks that: because orBec® did not achieve statistical sign...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

...rding the potential use of orBec® for the treatment of gastrointestinal gvhd and the prospects for regulatory filings for orBec®. Where possible, DO... factors which may affect the future use of orBec® for gastrointestinal gvhd include the risks that: because orBec® did not achieve statistical sign...
GVHD in Medical Dictionary

Graft Versus Host Disease

...lant against the patient", or " Graft - versus - Host " reaction. The complication is called " Graft - versus - Host Disease " (GvHD). What Types Of gvhd Exist? ... What is the risk for developing chronic graft - vs .- host disease (GVHD) after transplant? ... Diagnosis and Clinical Management...

Gastrointestinal

...e latest gastrointestinal , gastroenterology news headlines ... GastroIntestinal ... For OrBec(R) For The Treatment Of Chronic Gastrointestinal gvhd ... From screening and prevention to treatment of advanced gastrointestinal cancer, Fox Chase Cancer Center offers comprehensive care G...
GVHD in Biological News

Predicting acute GVHD by gene expression could improve liver stem cell transplant outcomes

Tampa, Fla. (July 21, 2008) Many cell transplants involve the use of stem cells from another human being (known as an allograft), which raises the major concern of the potential for acute graft-versus-host disease (GVHD). GVHD occurs when an immune response is elicited by the grafted cells agains...

REGiMMUNE presents enhanced efficacy data in preclinical transplantation models

...ts in the skin transplant model over Sirolimus single treatment. Likewise, gvhd mortality was reduced by the combination treatment. In addition, the combin...plans to file an Investigational New Drug (IND) for the prevention of acute gvhd associated with bone marrow transplantation later this year. The poster ...

U of M begins nation's first clinical trial using T-reg cells from cord blood in leukemia treatment

...ife-threatening graft-versus-host-disease (GVHD). gvhd occurs when the immune cells within the donated cells attack the body of the transplant recipient. gvhd causes one-third of deaths after transplant. Rese...dels, T-regs will be a powerful therapy to prevent gvhd and enhance engraftment in transplant patients. O...
GVHD in Biological Technology

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Or...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the seco...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

... that were observed were clearly of benefit to the gvhd patients," said Brian L. Hamilton, MD, PhD, Chief ...inal manifestation of GVHD, the organ system where gvhd is most frequently encountered and highly problema...Bec(R) is formulated for oral administration in GI gvhd patients as a single product consisting of two tab...

DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments

...firmatory Phase 3 clinical trial of orBec(R) in GI gvhd under a Special Protocol Assessment (SPA) with the...al trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiat...ct the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that...

Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations

... transplant procedures. Nevertheless, no cases of severe grade III/IV acute gvhd occurred after ATIR(TM) infusion. Furthermore, the clinical data showed a r... adequate immune reconstitution in combination with the prevention of acute gvhd in bone marrow transplantations using a mismatched donor. Dr. Denis-...

DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments

...key personnel to execute new clinical trials in GI gvhd and radiation enteritis. We are looking forward t...al trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiat...ct the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that...

DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the firs...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer

...on. His research focus was in the immunobiology of gvhd in an animal model. He also spent several years as...3 completion in GI GVHD. His specific expertise in gvhd will be vital to the successful interaction betwee...al trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiat...

Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants

... uses stem cells removed from a donor) is graft-versus-host disease (GVHD). gvhd is a potentially fatal complication that can occur when mature donor T cell...destroy residual cancerous cells while avoiding or controlling the T cells' gvhd response." Dr. Friedman continues: "Our Vß spectratype analysis is a powe...

Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA

...velopment as a treatment for patients with chronic gvhd resistant or intolerant to immunosuppressive agent...TM) treatment targets activated T cells that cause gvhd and results in immune modulation within patients w... achieve disease remission. About chronic GvHD gvhd is a condition that can develop after allogeneic b...
Other Tags
(Date:8/27/2014)... 27, 2014 With most forms ... sense to use hearing protection when exposed to ... are many different forms of hearing protection ... provide hearing protection training and devices for workers ... industries. The National Institute of Occupational Safety and ...
(Date:8/27/2014)... time you experienced worrisome medical symptoms, did you ... professional? If so, you,re not alone. Consumers are ... support groups to gather anecdotal information and advice, ... trustworthy sources. New research to be presented at ... the characteristics of consumers who use the Internet ...
(Date:8/27/2014)... 27, 2014 (HealthDay News) -- A new genetic discovery ... fight the bowel disorder, researchers report. The ... affect how their genes work, and said these changes ... raising the possibility of a simple diagnostic test for ... disease develops and suggest possible gene targets for new ...
(Date:8/27/2014)... An experimental drug designed to help regulate the blood,s iron ... of inflammation, according to results from the first human ... Blood , the Journal of the American ... occurs when red blood cells are in short supply or ... body does not get enough oxygen, since there are fewer ...
(Date:8/27/2014)... 8/27/14)Dartmouth cancer researchers developed and tested an advanced ... interactions that contribute to disease as published yesterday ... The approach fills a gap in current analyses. ... interactions among genetic and environmental factors. When many ... versus those that reflect chance combinations among affected ...
Breaking Medicine News(10 mins):Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 2Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 3Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
(Date:8/27/2014)... be found in both unprocessed and processed foods. Over ... been infected with Listeria from processed food, ... is notoriously difficult to fight because it has an ... surroundings, says Associate Professor Birgitte Kallipolitis, University of Southern ... and Molecular Biology, she has published a study, which ...
(Date:8/27/2014)... State University have found that century-old museum specimens hold clues ... pest that can weaken and kill trees and the ... insect populations increase on oak and maple trees in warmer ... also increase with global warming," says Dr. Elsa Youngsteadt, a ... paper on the work. , "More scale insects would be ...
(Date:8/26/2014)... colony of harmful bacteria, biofilms make the treatment ... a biofilm pose a significant health risk due ... and biofilm-protected bacteria account for some 80 percent ... 50 to 1,000 times more resistant to antibiotics ... may have stumbled onto a magic bullet," said ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3Museum specimens, modern cities show how an insect pest will respond to climate change 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
Other Contents